摘要
目的探讨AECOPD并发肺性脑病行无创辅助通气过程中应用右美托咪啶镇静的可行性及安全性。方法 AECOPD并发肺性脑病的患者68例,随机分为治疗组与对照组,每组34例。两组均给予无创通气支持、抗感染、平喘、支持等常规治疗;治疗组在常规治疗的基础上,加用治疗咪啶至满意的镇静状态。观察两组症状体征、血气变化情况、以及转归情况等。结果右美托咪啶组患者镇静效果满意,临床症状及化验指标明显优于对照组。结论右美托咪啶应用于AECOPD伴有肺性脑病行无创通气支持的患者,安全、效果理想,具有一定的临床应用前景。
Objective To explore the feasibility and safety of dexmedetomidine in the treatment of AECOPD patients complicated with pulmonary encephalopathy during NIPPV. Methods 68 AECOPD patients complicated with pulmonary encephalopathy were ran- domly divided into the treatment group and the control group. All patients received conventional therapy, including NIPPV, anti -infec- tion treatment, and cough relieve, and the treatment group were given dexmedetomidine additionally. The vital signs, blood gas changes, and turnover were observed and recorded. Results Patients in the treatment group had a satisfying sedative effect, and the improvement of blood gas analysis, clinical symptoms, and turnover was more pronounced in the treatment group than in the control group. Conclusion Dexmedetomidine is a safe and valuable therapy in the treatment of AECOPD patients complicated with pulmonary encephalopathy dur- ing N1PPV.
出处
《临床肺科杂志》
2013年第12期2212-2213,共2页
Journal of Clinical Pulmonary Medicine
